SecBot SecBot
EFFECT ·Filed Nov 13, 2026
WW

WWB

WINDWARD BIO GROUP AG
NEUTRAL
Impact 6/10
Horizondays Processed3d 21h ago SEC9999999995-26-003529
IPO/offering going effective
Actionable Insight • Neutral

Monitor the final IPO pricing and first-day trading performance. The concurrent Sanofi private placement signals strategic pharma interest, which may support valuation. Watch for the underwriters' 30-day option to purchase additional shares.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$28.50
T+0 close · Nov 13, 2026 · via day close
Latest settled
+5.40%
T+1 · $30.04
Vs SPY
+7.32%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $28.50entry
  2. T+1 · 15h ago +5.40%α +7.32% · $30.04
  3. T+5 · in 3d Pending
  4. T+20 · in 27d Pending
  5. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

The SEC declared effective Windward Bio Group AG's F-1 registration statement (File No. 333-299608) for its initial public offering of 10,294,117 common shares on Nasdaq under symbol WWB, at an estimated price range of $16.00-$18.00 per share. The IPO also includes a concurrent $50 million private placement with Sanofi. The company can now price and launch the offering, with trading expected to begin shortly.

Key Facts

  • EFFECT notice filed 2026-11-13, effective date 2026-11-12
  • Registration statement File No. 333-299608 declared effective
  • IPO of 10,294,117 common shares on Nasdaq under symbol WWB
  • Estimated price range $16.00-$18.00 per share
  • Concurrent $50 million private placement with Sanofi
  • Underwriters: Jefferies, TD Cowen, Piper Sandler, UBS Investment Bank
  • Company is a Swiss clinical-stage biotech developing ultra-long-acting antibody therapies
  • Lead candidates: WIN378 (anti-TSLP) and WIN027 (anti-TSLP/IL-13 bispecific)

Financial Impact

IPO of 10,294,117 shares at $16-$18 per share implies gross proceeds of approximately $165M-$185M; plus $50M private placement with Sanofi

dilutioncash

Risk Factors

  • No public market currently exists for WWB shares; first-day price volatility expected
  • Clinical-stage biotech with no approved products; high execution risk
  • Dilution from IPO and private placement
  • Nasdaq listing approval not yet guaranteed

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (Primary)9999999995-26-003529
Document: 9999999995-26-003529-index.html9999999995-26-003529
Document: 9999999995-26-003529.txt9999999995-26-003529

US Market Status

Market Closed · Opens Wed (11h 57m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 13, 2026